Zydus Cadila has received tentative approval from the US Food and Drug Administration (USFDA) to market Carbidopa and Levodopa Extended-Release Capsules (US RLD - Rytary) in the strengths of 23.75 mg/95 mg, 36.25 mg/145 mg, 48.75 mg/195 mg, and 61.25 mg/245 mg.
This medication is used to treat the symptoms of Parkinson’s disease (such as shakiness, stiffness, difficulty moving) or Parkinson-like conditions. The drug will be manufactured at the group's formulation manufacturing facility at SEZ, Ahmedabad.
The group now has 295 approvals and has so far filed over 390 ANDAs since the commencement of the filing process in FY 2003-04.
Cadila Healthcare is an India-based pharmaceutical company. The company's subsidiaries include Zydus Wellness, Liva Pharmaceuticals, Biochem Pharmaceutical Industries, Zydus Technologies, German Remedies, Dialforhealth India, Dialforhealth Unity and Dialforhealth Greencross, among others.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1483.75 |
Dr. Reddys Lab | 5947.30 |
Cipla | 1347.70 |
Zydus Lifesciences | 958.90 |
Lupin | 1580.00 |
View more.. |